Bharat Parenterals Limited (BOM:541096)
1,527.95
-7.00 (-0.46%)
At close: Sep 4, 2026
Bharat Parenterals Revenue
Bharat Parenterals had revenue of 937.37M INR in the quarter ending June 30, 2026, a decrease of -19.19%. This brings the company's revenue in the last twelve months to 3.23B, down -11.19% year-over-year. In the fiscal year ending March 31, 2026, Bharat Parenterals had annual revenue of 3.45B with 1.48% growth.
Revenue (ttm)
3.23B
Revenue Growth
-11.19%
P/S Ratio
3.26
Revenue / Employee
8.00M
Employees
404
Market Cap
10.53B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.45B | 50.49M | 1.48% |
| Mar 31, 2025 | 3.40B | 791.65M | 30.31% |
| Mar 31, 2024 | 2.61B | 419.14M | 19.11% |
| Mar 31, 2023 | 2.19B | 69.72M | 3.28% |
| Mar 31, 2022 | 2.12B | 51.08M | 2.46% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.88B |
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Kopran | 7.00B |
| Lincoln Pharmaceuticals | 6.94B |
| Wanbury | 6.53B |
| Amrutanjan Health Care | 5.11B |
| Fermenta Biotech | 5.11B |
Bharat Parenterals News
- 9 months ago - Bharat Parenterals’ subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations - Business Upturn
- 9 months ago - Bharat Parenterals subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations - Business Upturn